Ivlan (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, which slows the spontaneous depolarisation that sets the heart’s rhythm. This results in a lower resting heart rate while preserving contractile strength and blood pressure, supporting better cardiac efficiency.

The dose of Ivlan is individualized by the prescribing clinician based on the patient’s condition, heart‑rate response, and tolerability. Healthcare providers follow regional guidelines and may start with a low dose, titrating as needed while monitoring heart rate and symptoms.

Safety data for ivabradine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Ivlan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ivabradine differs from beta‑blockers, the traditional heart‑rate‑lowering class, because it reduces heart rate without affecting myocardial contractility or blood pressure. It is often considered when beta‑blockers are contraindicated, not tolerated, or when additional heart‑rate control is needed.

Ivlan tablets should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date.

Ivlan is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include new‑onset atrial fibrillation, severe bradycardia that may cause dizziness or syncope, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience palpitations, fainting, or severe visual changes.

Ivlan is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block, or those with uncontrolled atrial fibrillation. It should also be avoided in individuals taking strong CYP3A4 inhibitors without appropriate dose adjustment.